213 related articles for article (PubMed ID: 33309691)
1. Biosimilars for Retinal Diseases: An Update.
Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
Am J Ophthalmol; 2021 Apr; 224():36-42. PubMed ID: 33309691
[TBL] [Abstract][Full Text] [Related]
2. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
Zhang C; Friedman S; Mruthyunjaya P; Parikh R
Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
[TBL] [Abstract][Full Text] [Related]
3. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.
Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
Expert Opin Biol Ther; 2023; 23(8):689-692. PubMed ID: 37470687
[TBL] [Abstract][Full Text] [Related]
4. Razumab -- the role of biosimilars for the treatment of retinal diseases.
Ferro Desideri L; Cutolo CA; Traverso CE; Nicolò M
Drugs Today (Barc); 2021 Aug; 57(8):499-505. PubMed ID: 34405207
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.
Bressler NM; Kaiser PK; Do DV; Nguyen QD; Park KH; Woo SJ; Sagong M; Bradvica M; Kim MY; Kim S; Sadda SR
Surv Ophthalmol; 2024; 69(4):521-538. PubMed ID: 38521423
[TBL] [Abstract][Full Text] [Related]
6. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.
Kaiser PK; Schmitz-Valckenberg MS; Holz FG
Retina; 2022 Dec; 42(12):2243-2250. PubMed ID: 36394884
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview.
Viola P; Testa V; Ferro Desideri L; Di Cello L; Rutigliani C; Vagge A; Nicolò M; Cian R; Traverso CE
Drugs Today (Barc); 2021 Nov; 57(11):689-697. PubMed ID: 34821882
[TBL] [Abstract][Full Text] [Related]
8. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in the Treatment of Retinal Disease in the United States.
Vakharia PS; Eichenbaum DA; Baumal CR
Ophthalmic Surg Lasers Imaging Retina; 2023 Jun; 54(6):362-366. PubMed ID: 37222553
[TBL] [Abstract][Full Text] [Related]
10. Ophthalmic biosimilars: Lessons from India.
Sharma A; Kumar N; Kuppermann BD; Francesco B; Lowenstein A
Indian J Ophthalmol; 2019 Aug; 67(8):1384-1385. PubMed ID: 31332154
[No Abstract] [Full Text] [Related]
11. Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs.
Marko CK; Miller JW
J Law Med Ethics; 2021; 49(1):19-24. PubMed ID: 33966647
[TBL] [Abstract][Full Text] [Related]
12. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
13. Intraocular use of bevacizumab in India: An issue resolved?
Kumar A; Tripathy K; Chawla R
Natl Med J India; 2017; 30(6):345-347. PubMed ID: 30117450
[TBL] [Abstract][Full Text] [Related]
14. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
16. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
Li E; Greenberg PB; Voruganti I; Krzystolik MG
R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
[TBL] [Abstract][Full Text] [Related]
17. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
Katz G; Zehavi C; Treister G
Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic.
Billioti de Gage S; Drouin J; Desplas D; Cuenot F; Dray-Spira R; Weill A; Zureik M
JAMA Ophthalmol; 2021 Feb; 139(2):240-242. PubMed ID: 33331873
[TBL] [Abstract][Full Text] [Related]
19. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
20. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration.
Mantel I; Gillies MC; Souied EH
Surv Ophthalmol; 2018; 63(5):638-645. PubMed ID: 29476754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
